Synapse - Biomed Central Ltd

Biomed Central Ltd

SHERPA: Unknown

People

Vickers
Postow
D'Angelo
Offit
Budhu
Motzer
Shoushtari
Cheung
Voss
O'Reilly

Groups

Department of Medicine (566)
Solid Tumor Oncology Division (461)
GSK Faculty (295)
Sloan Kettering Institute Postdocs (194)
Hematologic Malignancies, Division of (160)
Population Sciences Research Program (158)
Epidemiology and Biostatistics (153)
Melanoma and Immunotherapeutics Service (148)
Surgery (123)
Survivorship Research (120)

Search Within

Results (1092)

Export to EndNote / Excel

Commensal bacteria Bifidobacterium stimulates an anti-tumor response via cross-reactivity

Meeting Abstract

Bessell, C.; Bessell, C.; Isser, A.; Havel, J.; Lee, S.; Zhou, R.; Schneck, J.; Bell, D.
Journal for ImmunoTherapy of Cancer (2018)

Fulltext@MSK | Save

T cell immunotherapies trigger innate immunity and aseptic inflammation leading to potent anti-tumor and off-targets effects

Meeting Abstract

Hirschhorn-Cymerman, D.; Ricca, J.; Gasmi, B.; De Henau, O.; Mangarin, L.; Budhu, S.; Li, Y.; Cortez, C.; Liu, C.; Zappasodi, R.; more...
Journal for ImmunoTherapy of Cancer (2018)

Fulltext@MSK | Save

TCR repertoire correlates of response in tumor-bearing mice treated with radiotherapy and CTLA-4 blockadeRudqvis

Meeting Abstract

Rudqvist, N. P.; Lhuillier, C.; Wennerberg, E.; Sims, J.; Demaria, S.
Journal for ImmunoTherapy of Cancer (2018)

Fulltext@MSK | Save

Targeting phosphatidylserine enhances the anti-tumor response to radiation therapy and immune checkpoint blockade in a preclinical melanoma model

Meeting Abstract

Budhu, S.; Giese, R.; Gupta, A.; Schad, S.; De Henau, O.; Zappasodi, R.; Campesato, L.; Barker, C.; Wolchok, J.; Merghoub, T.
Journal for ImmunoTherapy of Cancer (2018)

Fulltext@MSK | Save

Developing a cross-reactive heteroclitic peptide cancer vaccine targetting poorly immunogenic mutant calreticulin in myeloproliferative neoplasms

Meeting Abstract

Gigoux, M.; Elf, S.; Ciboddo, M.; Zappasodi, R.; Pourpe, S.; Abdelfattah, N.; Chan, T.; Abdel-Wahab, O.; Mullally, A.; Merghoub, T.; more...
Journal for ImmunoTherapy of Cancer (2018)

Fulltext@MSK | Save

Rational combination of GITR agonism with PD-1 blockade in cancer patients

Meeting Abstract

Zappasodi, R.; Sirard, C.; Li, Y.; Budhu, S.; Abu-Akeel, M.; Liu, C.; Yang, X.; Zhong, H.; Newman, W.; Qi, J.; more...
Journal for ImmunoTherapy of Cancer (2018)

Fulltext@MSK | Save

HLA class I subtypes are associated with immune-related adverse events in patients with melanoma treated with ipilimumab

Meeting Abstract

Safonov, A.; Pluta, J.; Qian, L.; Amaravadi, R.; Applegate, A.; Buchbinder, E.; Cohen, J.; Friedman, C.; Halaban, R.; Hodi, F. S.; more...
Journal for ImmunoTherapy of Cancer (2018)

Fulltext@MSK | Save

Preliminary evidence of intratumoral activation and immunomodulatory effect of CX-072, a Probody therapeutic antibody prodrug targeting PD-L1, in a phase 1/2a trial

Meeting Abstract

Lyman, S. K.; Gordon, J.; DuPage, A.; Pramanik, P.; Howng, B.; Winter, M. B.; Popova, I. K.; Vasiljeva, O.; Jones, J.; Wong, K.; more...
Journal for ImmunoTherapy of Cancer (2018)

Fulltext@MSK | Save

First-in-human study of FAZ053, an anti-PD-L1 mAb, alone and in combination with spartalizumab, an anti-PD-1 mAb, in patients with advanced malignancies